Clinical trial · Interventional
Study of BMS-986158 in Subjects With Select Advanced Cancers
A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies
NCT02419417CI-TRIAL-00059148BETcompletedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Tumors | Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986158 | Drug | — | UNRESOLVED |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Monotherapy Treatment
- description
- Patients treated at various doses and schedules
- interventionNames
- Drug: BMS-986158
- type
- EXPERIMENTAL
- label
- Combination Therapy
- description
- Patients treated at selected doses and schdules
- interventionNames
- Drug: BMS-986158
- Biological: Nivolumab
Primary outcomes (2)
- measure
- Number of Participants Experiencing Adverse Events
- timeFrame
- From first dose to 30 days following last dose (up to approximately 29 months)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * Must have select advanced cancers with specific genetic profiles * Must have received appropriate standard of care * At least one measurable lesion at baseline * Expected to have life expectancy of at least 3 months * Eastern Cooperative Oncology Group (ECOG) of 0 to 1 Exclusion Criteria: * Concomitant second malignancies * Uncontrolled or significant cardiovascular disease * Inadequate bone marrow function * Chronic gastrointestinal illness * Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.